相关实验视频

Updated: Sep 13, 2025

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

从全国范围的日本队列对转移性肝脏瘤颗粒疗法的数据进行了全面的分析

Nobuyoshi Fukumitsu¹, Shintaro Shiba², Kei Shibuya³

¹Department of Radiation Oncology, Kobe Proton Center.

International journal of radiation oncology, biology, physics

|July 28, 2025

概括

颗粒疗法 (PT) 对转移性肝脏瘤具有前景,提供优良的局部控制和低毒性. 有希望的生存率,特别是对于结肠直肠癌和乳腺癌患者,表明潜在的生存优势.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

转移性肝脏瘤在癌症治疗中是一个重大挑战.
粒子疗法 (PT) 是一种先进的辐射技术,具有精确瘤向的潜力.
评估PT在肝转移中的有效性和安全性对于扩大治疗选择至关重要.

研究的目的:

评估粒子治疗 (PT) 对转移性肝脏瘤患者的有效性和安全性.
确定与PT相关的整体生存率 (OS) 和不良事件在这个患者群体.
评估PT作为治疗有限的肝转移的潜力.

主要方法:

一个全国性的,多机构的回顾性队列研究,对用质子束疗法或碳离子放射治疗治疗的患者进行治疗.
包括322名在2016年至2019年期间被诊断患有转移性肝脏瘤的患者.
评估整体生存 (OS),无进展生存 (PFS),局部控制 (LC) 和严重毒性 (等级≥3).

主要成果:

2年和5年的生存率分别为55.7%和32.8% (平均存活时间为28.6个月).
在单个病变,较小的瘤 (<5厘米) 和特定癌症 (结肠直肠,乳腺,胰腺,胃,食道) 的患者中观察到更好的生存率.
报告了高的局部控制率 (2年:74.3%,5年:66.4%) 和低的不良事件 (3.1%).

结论:

颗粒疗法显示出出色的局部控制和转移性肝脏瘤的良好的安全性.
对于精心挑选的患者,特别是患有结直肠和乳腺癌的患者,PT提供了生存优势.
进一步的研究应该专注于优化PT策略,用于各种转移性肝脏瘤呈现.

关键词:

质子束疗法是一种质子束疗法.碳离子辐射疗法转移性肝脏瘤的发生.粒子束疗法是一种粒子束疗法.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...